Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response and Survival Outcomes

NCT06901934 is registered in ClinicalTrials.gov with Zeinab Yahia Zaki as lead sponsor.

NCT NCT06901934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06901934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response and Survival Outcomes
Lead sponsor
Zeinab Yahia Zaki
Phase
Observational
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
October 1, 2028
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma bladder